Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 201 - Artiva Biotherapeutics

Next Previous
Drug Profile

AB 201 - Artiva Biotherapeutics

Alternative Names: AB-201 - Artiva Biotherapeutics

Latest Information Update: 06 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GC Lab Cell
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Gastric cancer; Gastrointestinal cancer

Most Recent Events

  • 24 Jan 2025 GC Lab Cell withdraws a phase I trial prior to enrollment for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in Australia (Parenteral) (NCT06341647)
  • 02 Apr 2024 GC Lab Cell plans a phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in Australia (Parenteral), in August 2024 (NCT06341647)
  • 10 Jan 2024 Preclinical trials in Gastric cancer in South Korea, USA (Parenteral) (NCT05678205)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top